An unusual false-positive uptake of radioiodine caused by pulmonary vasculature: The usefulness of SPECT/CT

Hell J Nucl Med 2020; 23(2): 204-205 Published online: 24 August 2020




Figure 1. A 25-year-old woman with differentiated papillary thyroid cancer was referred for 131 therapy after total thyroidectomy and cervical lymph node dissection. The patient was administered 3.7GBg of ¹³¹l. Anterior (A) and posterior (B) whole body images obtained 8 days after ¹³¹l administration revealed increased activity in the left dental caries, thyroid bed, and left IV-zone cervical lymph node and in the right chest (arrows). To clarify the nature of the focal activity in her right chest, SPECT/CT images were acquired.




Figure 2. CT (A, B) and SPECT/CT (C, D) localized the activity to the pulmonary vasculature of the basal segment of the right lower lobe (arrows). CT demonstrated no abnormal density shadow. The thyroglobulin level was 18.64ng/mL, the TgAb >500u/mL, the TSH >150uIU/mL, and the patient had no complaint related to her lung.

There are numerous conditions that may cause false-positive findings on iodine scintigraphy, such as vascular structure, mediastinum, bronchiectasis, cystic lesions, and mature cystic teratoma [1-8]; however, many of their mechanisms remain to be elucidated [9, 10]. Single photon emission computed tomography/computed tomography (SPECT/CT) imaging can be conducive to avoiding potential pitfalls [11-13]. In addition, the nuclear physicians have to bear in mind that iodine-131 (¹³¹l) uptake in pulmonary vasculature can be a possible cause of false-positive uptake when they interpret ¹³¹l whole body scan (WBS).

The authors declare that they have no conflicts of interest.

Bibliography

- 1. Yazici B, Oral A, Omur O et al. Radioiodine uptake in an ovarian mature teratoma detected with SPECT/CT. Clin Nucl Med 2015; 40: e157-160.
- 2. Lee M, Lee YK, Jeon TJ et al. ¹³¹ I uptake in intraosseous hemangioma of the skull: mimicking a bone metastasis in thyroid cancer. *Clin Nucl* Med 2014; 39: 990-2.
- 3. Ciappuccini R, Aide N, Métayer L et al. Unusual ¹³¹ lodine uptake in a joint demonstrated by SPECT/CT in a patient with differentiated thyroid cancer. *Clin Nucl Med* 2015; 40: 332-4.
- 4. Mi YX, Sui X, Huang JM et al. Incidentally polycystic kidney disease identified by SPECT/CT with post-therapy radioiodine scintigraphy in a patient with differentiated thyroid carcinoma: A case report. *Medicine (Baltimore)* 2017; 96: 43(e8348).
- 5. Shen GH, Qi ZZ, Huang R et al. False-Positive Uptake of Radioiodine in Renal Hamartoma in a Patient With Differentiated Thyroid Cancer. *Clin Nucl Med* 2017; 42:709-10.
- 6. Oral A, Yazici B, Eraslan C et al. Unexpected False-positive I-131 Uptake in Patients with Differentiated Thyroid Carcinoma. *Mol Imaging Radionucl Ther* 2018; 27:99-106.
- 7. Liu B, Kaplan SL, Yang H et al. Constipation causing elevated iodine activity in the rectum mimicking thyroid cancer metastases. *Clin Nucl Med* 2015; 40:442-5.
- 8. Triggiani V, Giagulli VA, Iovino M et al. False positive diagnosis on 131-lodine whole-body scintigraphy of differentiated thyroid cancers. *Endocrine* 2016; 53: 626-35.
- 9. Oh JR, Ahn BC. False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer. *Am J Nucl Med Mol Imaging* 2012; 2:362-85.
- 10. Chudgar AV, Shah JC. Pictorial Review of False-Positive Results on Radioiodine Scintigrams of Patients with Differentiated Thyroid Cancer. *RadioGraphics* 2017: 37: 298-315.
- 11. Oh JR, Jeong SY, Yoon H et al. Incompletely dissolved radioiodine capsule as a likely cause of false-positive whole-body scan in thyroid cancer. *Clin Nucl Med* 2015: 40: 177-8.
- 12. Hannoush ZC, Palacios JD, Kuker RA et al. False Positive Findings on I-131 WBS and SPECT/CT in Patients with History of Thyroid Cancer: Case Series. Case Rep Endocrinol 2017; 2017: 8568347.
- $13.\ Zhao\,Z, Zhou\,K, Liu\,B.\,Added\,value\,of\,SPECT/CT\,in\,the\,evaluation\,of\,sacral\,fracture\,in\,patients\,with\,lung\,cancer.\,\textit{Clin\,Nucl\,Med}\,2018; 43:e195-e197.$

Fanhui Yang¹ MD, Lingzhi Cao² MD, Chunyin Zhang³ MD*

1. Department of Nuclear Medicine, The Affiliated Hospital of North Sichuan Medical College, No.1, Maoyuan South Road, 637000 Nanchong, Sichuan province, P.R.China. Email: yangfanhui.2008@163.com, 2. Department of Nuclear Medicine, The Affiliated Hospital of North Sichuan Medical College, No.1, Maoyuan South Road, 637000 Nanchong, Sichuan province, P.R.China. Email: cbyxyclz@163.com, 3. Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, No. 25, Taiping St., 646000 Luzhou, Sichuan province, P.R.China. Email: zhangchunyin345@163.com

Fanhui Yang and Lingzhi Cao contributed equally to this work.

Corresponding author: Chunyin Zhang, Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, No. 25, Taiping St.,646000 Luzhou, Sichuan province, P.R.China. Email: zhangchunyin345@163.com

